

## NOVEL IMIDAZOLINE RECEPTOR HOMOLOGS

### FIELD OF THE INVENTION

The invention relates to nucleic acid and amino acid sequences of novel  
5 imidazoline receptors and to the use of these sequences in the treatment of physical and neurological disorders.

### BACKGROUND OF THE INVENTION

Imidazoline receptor (IMR) subtypes bind clonidine and imidazoline (Escriba et al., 1995). These compounds mediate the regulation of blood pressure, induction of feeding, stimulation of firing of locus coeruleus neurons, and stimulation of insulin release, as well as the induction of the expression of glial fibrillary acidic protein independent of the action of alpha-2 adrenoceptors. These receptors are pharmacologically important target for drugs that can mediate the aforementioned physiological conditions (Farsang and Kapocsi, 1999).

Non-adrenoceptor sites predominantly labeled by clonidine or para-amino clonidine are termed I<sub>1</sub>-sites whereas those non-adrenoceptor sites predominantly labeled by idazoxan are termed I<sub>2</sub>-sites. Imidazoline sites which are distinct from either I<sub>1</sub>- or I<sub>2</sub> sites are termed I<sub>3</sub>-sites. An example is an imidazoline receptor in the pancreas reported to enhance insulin secretion. Chan et al. (1993) *Eur. J. Pharmacol.* 230 375; Chan et al. (1994) *Br. J. Pharmacol.* 112 1065. The receptor is efaroxan sensitive and it a target for the treatment of type II diabetes. The site is  
20 also sensitive to agmatine, an insulin secretagogue, and to crude preparation of clonidine displacing substance (CDS).

Endogenous ligands of the imidazoline receptors are harmane, tryptamine and agmatine. There are also numerous compounds which are selective for either I<sub>1</sub>-sites, e.g., clonidine, benazoline and rilmenidine, or I<sub>2</sub>-sites, e.g. RS-45041-190, 2-BFI, BU 224, and BU 239. Many  
25 of these compounds are commercially available, for example, from Tocris Cookson, Inc., USA.

I<sub>1</sub>-site selective drugs are promising for the treatment of hypertension, I<sub>3</sub>-site selective drugs are promising for the treatment of diabetes, and I<sub>2</sub>-site selective drugs affect monoamine

turnover and therefore I<sub>2</sub> receptor ligands can affect a wide range of brain functions such as nociception, ageing, mood and stroke.

### SUMMARY OF THE INVENTION

The present invention relates to a novel imidazoline receptor homologs, hereinafter designated imidazoline receptor related protein 1 (IMRRP1), imidazoline receptor related protein 1b (IMRRP1b) and derivatives thereof.

Accordingly, the invention relates to a substantially purified IMRRP1 having the amino acid sequence of Figure 3 (SEQ ID NO: 3), or functional portion thereof, and substantially purified IMRRP1b having the amino acid sequence of Figure 4 (SEQ ID NO: 4).

The present invention further provides a substantially purified soluble IMRRP1. In a particular aspect, the soluble IMRRP1 comprises the amino acid sequence of Figure 3 (SEQ ID NO: 3). The present invention further provides a substantially purified soluble IMRRP1b. In a particular aspect, the soluble IMRRP1b comprises the amino acid sequence of Figure 4 (SEQ ID NO: 4).

The present invention provides pharmaceutical compositions comprising at least one IMRRP1, IMRRP1b or a functional portion thereof.

The present invention also provides methods for producing IMRRP1, IMRRP1b or a functional portion thereof.

One aspect of the invention relates to isolated and substantially purified polynucleotides that encode IMRRP1 or IMRRP1b. In a particular aspect, the polynucleotide comprises the nucleotide sequence of Figure 1 (SEQ ID NO: 1). In another aspect of the invention, the polynucleotide comprises the nucleotide sequence which encodes IMRRP1. In another aspect, the polynucleotide comprises the nucleotide sequence of Figure 2 (SEQ ID NO: 2). In another aspect of the invention, the polynucleotide comprises the nucleotide sequence which encodes IMRRP1b.

The invention also relates to a polynucleotide sequence comprising the complement of Figures 1 or 2 (SEQ ID NO: 1 or 2) or variants thereof. In addition, the invention

features polynucleotide sequences which hybridize under stringent conditions to a polynucleotide sequence of Figures 1 or 2 (SEQ ID NO: 1 or 2).

The invention further relates to nucleic acid sequences encoding polypeptides, oligonucleotides, fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode IMRRP1 or IMRRP1b.

It is another object of the present invention to provide methods for producing polynucleotide sequences encoding an imidazoline receptor.

Another aspect of the invention is antibodies which bind specifically to an imidazoline receptor or epitope thereof, for use as therapeutics and diagnostic agents.

Another aspect of the invention is an agonist, antagonist or inverse agonist of IMRRP1 or IMRRP1b.

The present invention provides methods for screening for agonists, antagonists and inverse agonists of the imidazoline receptors.

It is another object of the present invention to use the nucleic acid sequences, polypeptide, peptide and antibodies for diagnosis of disorders or diseases associated with aberrant regulation of blood pressure, induction of feeding, stimulation of firing of locus coeruleus neurons, and stimulation of insulin release, as well as the aberrant induction of the expression of glial fibrillary acidic protein independent of the action of alpha-2 adrenoceptors, dysphoric premenstrual syndrome, neurodegenerative disorders such as Alzheimer's disease, opiate addiction, monoamine turnover and therefore nociception, ageing, mood and stroke, salivary disorders and developmental disorders.

The present invention provides methods of preventing or treating disorders associated with aberrant regulation of blood pressure, induction of feeding, stimulation of firing of locus coeruleus neurons, and stimulation of insulin release, as well as methods of preventing or treating disorders associated with the aberrant induction of the expression of glial fibrillary acidic protein independent of the action of alpha-2 adrenoceptors, dysphoric premenstrual syndrome, neurodegenerative disorders such as Alzheimer's disease, opiate addiction,

monoamine turnover and therefore nociception, ageing, mood and stroke, salivary disorders and developmental disorders.

The present invention provides kits for screening and diagnosis of disorders associated with aberrant IMRRP1 or IMRRP1b.

5

## BRIEF DESCRIPTION OF THE FIGURES

These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the detailed description of the invention when considered in connection with the accompanying drawings wherein:

**Figures 1A and B** show the polynucleotide sequence from Clone No. FL1-18 (SEQ ID NO: 1). Clone No. FL1-18 was deposited as ATCC Deposit No. PTA-2671 on November 15, 2000 at the American Type Culture Collection, Patent Depository, 10801 University Boulevard, Manassas, Va. 20110-2209

**Figures 2A-C** show the polynucleotide sequence from Clone No. FL1-18 splice variant (SEQ ID NO: 2).

**Figure 3** shows the polypeptide sequence from IMRRP1 (SEQ ID NO: 3).

**Figure 4** shows the polypeptide sequence from IMRRP1b (SEQ ID NO: 4).

**Figure 5** shows the comparison of IMRRP1 and human imidazoline receptor Accession Number NP\_009115.

**Figure 6** shows the comparison of FL1-18 to Incyte 2499870. Top strand, FL1-18; bottom strand, Incyte 2499870.

**Figures 7A and B** show the comparison of FL1-18 splice variant to *Drosophila melanogaster* CG9044, and human imidazoline receptor Accession Number NP\_009115.

**Figures 8A-D** show a comparison of FL1-18 splice variant, FL1-18, *Drosophila melanogaster* CG9044, and human imidazoline receptor Accession Number NP\_009115

**Figure 9** shows the expression profile of IMRRP1.

**Figure 10** shows the expression profile of IMRRP1.

### DESCRIPTION OF THE INVENTION

“Nucleic acid sequence”, as used herein, refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, “amino acid sequence” as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic molecules.

Where “amino acid sequence” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms, such as “polypeptide” or “protein” are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

“Peptide nucleic acid”, as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al (1993) *Anticancer Drug Des.*, 8:53-63).

IMRRP1 and IMRRP1b, as used herein, refer to the amino acid sequences of substantially purified imidazoline receptor related proteins obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

“Consensus”, as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR (Perkin Elmer, Norwalk, Conn.) in the 5' and/or the 3' direction and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte clone or publically available clone using the GELVIEW Fragment Assembly system (GCG, Madison, Wis.), or which has been both extended and assembled.

A “variant” of IMRRP1 or IMRRP1b, as used herein, refers to an amino acid

sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

A "deletion", as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic imidazoline receptor, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which when bound to IMRRP1 or IMRRP1b, increases the amount of, or prolongs the duration of, the activity of IMRRP1 or IMRRP1b. Agonists may include proteins, nucleic acids, carbohydrates, organic molecules or any other molecules which bind to IMRRP1 or IMRRP1b.

The term "antagonist", as used herein, refers to a molecule which, when bound to IMRRP1 or IMRRP1b, decreases the biological or immunological activity of IMRRP1 or IMRRP1b. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates,

organic molecules or any other molecules which bind to IMRRP1 or IMRRP1b.

The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of IMRRP1 or IMRRP1b or portions thereof and, as such, is able to effect some or all of the actions of IMRRP1 or IMRRP1b.

5           The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding IMRRP1 or IMRRP1b or the encoded IMRRP1 or IMRRP1b. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

10           The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% or greater free from other components with which they are naturally associated.

15           "Amplification", as used herein, refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, D.W. and G. S. Dveksler (1995), *PCR Primer, a Laboratory Manual*, Cold Spring Harbor Press, Plainview, NY).

20           The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

25           The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed *in situ* hybridization).

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition,



presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

5           The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about  $T_m - 5^\circ\text{C}$ . ( $5^\circ\text{C}$ . below the melting temperature  $T_m$  of the probe) to about  $20^\circ\text{C}$ . to  $25^\circ\text{C}$ . below  $T_m$ . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

10           The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a  
15           complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

20           The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO: 3 or 4" encompasses the full-length human IMRRP1 or IMRRP1b and fragments thereof.

25           "Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method

for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and partial bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding IMRRP1 or IMRRP1b or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NOS: 1 or 2 by northern analysis is indicative of the presence of mRNA encoding IMRRP1 and IMRRP1b in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NOS: 1 and 2 as used herein, comprise any alteration in the sequence of polynucleotides encoding IMRRP1 and IMRRP1b including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes IMRRP1 or IMRRP1b (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NOS: 1 or 2), the inability of a selected fragment of SEQ ID NOS: 1 or 2 to hybridize to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding IMRRP1 or IMRRP1b (e.g., using fluorescent *in situ* hybridization (FISH) to metaphase chromosome spreads).

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')<sub>2</sub>, Fv, chimeric antibody, single chain antibody which are capable of binding the epitopic determinant. Antibodies that bind IMRRP1 or IMRRP1b polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest or prepared recombinantly for use as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from the transition of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize the animal, e.g., a mouse, a rat, or a rabbit.

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more

closely resemble a human antibody, while still retaining the original binding ability.

The deposit(s) referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, or sell the deposited materials, and no such license is hereby granted.

The invention is novel human imidazoline receptors referred to as IMRRP1 and IMRRP1b, polynucleotides encoding IMRRP1 and IMRRP1b, and the use of these compositions for the diagnosis, prevention, or treatment of disorders associated with aberrant cellular development, immune responses and inflammation, as well as organ and tissue transplantation rejection.

Human imidazoline receptor protein sequence was used as a probe to search the Incyte and public domain EST databases. The search program used was gapped BLAST (Altschul et al., 1997). The top EST hits from the BLAST results were searched back against the non-redundant protein and patent sequence databases. From this analysis, ESTs encoding a potential novel imidazoline receptor was identified based on sequence homology. The Incyte EST (Clone ID: 2499870) was selected as a potential novel imidazoline receptor candidate for subsequent analysis.

A PCR primer pair, designed from the DNA sequence of Incyte clone-2499870 was used to amplify a piece of DNA from the clone in which the anti-sense strand of the amplified fragment was biotinylated on the 5' end. This biotinylated piece of double stranded DNA was denatured and incubated with a mixture of single-stranded covalently closed circular cDNA libraries which contain DNA corresponding to the sense strand. The cDNA libraries were total brain tissue libraries obtained from Gibco Life Technologies. Hybrids between the

biotinylated DNA and the circular cDNA were captured on streptavidin magnetic beads. Upon thermal release of the cDNA from the biotinylated DNA, the single stranded cDNA was converted into double strands using a primer homologous to a sequence on the cDNA cloning vector. The double stranded cDNA was introduced into *E. coli* by electroporation and the resulting colonies were screen by PCR, using the original primer pair to identify the proper cDNA clones. One clone named FL1-18 was sequenced on both strands (Figure 1). The deduced amino acid sequence corresponding to the nucleic acid sequence of clone FL1-18 is shown in Figure 3.

A comparison of the FL1-18 cDNA to that of the partial clone found in the Incyte database (clone 2499870) revealed that at nucleotide position 1725 of the Incyte clone a small insertion of 25 bases occurs and at position 3375 of clone FL1-18 an insertion of 47 bases occurs. (See Figure 6: Top strand, FL1-18; bottom strand, Incyte 2499870.) An alignment of the two DNA sequences, FL1-18 and Incyte 2499870 is shown in Figure 8..

An alignment of the two DNA sequences, FL1-18 and Incyte 2499870 to the rough draft of the human genome, revealed that both insertions/deletion in the two sequences correspond to putative exons as determined by the conservation of splice donor and acceptor sequences on either side of the inserted DNA and hence represent different RNA splice forms of a transcript that originates from one genomic location (i.e., one gene).

The Incyte clone is missing approximately 450 bp of the 5'-end. Combining the 5'-end sequences of FL1-18 sequence with that of the Incyte clone creates a novel nucleotide sequence which is referred to the FL1-18 splice variant. Translation of this sequence produces a longer polypeptide chain than that of FL1-18 because of the elimination of an in frame stop caused by the lack of the small exon in FL1-18. The first 712 amino acid are identical, but after that the remaining 97 amino acids of FL1-18 differ. The second alternatively spliced exon found in the Incyte clone is a coding exon. Hence, these splice variants produce different length and possibly different functional proteins.

In one embodiment, the invention encompasses a polypeptide comprising the

amino acid sequence of SEQ ID NO: 3 as shown in Figure 3, or the amino acid sequence of SEQ ID NO: 4 as shown in Figure 4. IMRRP1 and IMRRP1b share chemical and structural homology with the human imidazoline receptor, Accession number NP\_009115. IMRRP1 and IMRRP1b also share chemical and structural homology with two *Drosophila* proteins identified as Accession number AAF52305 and Accession number AAF57514. IMRRP1 shares 26% identity with the human imidazoline receptor, Accession number NP\_009115, as illustrated in Figure 5.

Expression profiling of imidazoline receptor homolog IMRRP1 showed expression in a variety of human tissue. The same PCR primer used in the cloning of imidazoline receptor IMRRP1 was used to measure the steady state levels of mRNA by quantitative PCR. Briefly, first strand cDNA was made from commercially available mRNA. The relative amount of cDNA used in each assay was determined by performing a parallel experiment using a primer pair for a gene expressed in equal amounts in all tissues, cyclophilin. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the primer pair for IMRRP1. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in Figure 9.

The invention also encompasses IMRRP1 and IMRRP1b variants. Preferred IMRRP1 and IMRRP1b variants are those having at least 80%, and more preferably 90% or greater, amino acid identity to the IMRRP1 and IMRRP1b amino acid sequence of SEQ ID NOS: 3 and 4, respectively. Most preferred IMRRP1 and IMRRP1b variants are those having at least 95% amino acid sequence identity to SEQ ID NOS: 3 and 4, respectively.

The present invention provides isolated IMRRP1 and IMRRP1b and homologs thereof. Such proteins are substantially free of contaminating endogenous materials and, optionally, without associated nature-pattern glycosylation. Derivatives of the IMRRP1 and IMRRP1b receptors within the scope of the invention also include various structural forms of the primary protein which retain biological activity. Due to the presence of ionizable amino and

carboxyl groups, for example, IMRRP1 and IMRRP1b proteins may be in the form of acidic or basic salts, or may be in neutral form. Individual amino acid residues may also be modified by oxidation or reduction.

5 The primary amino acid structure may be modified by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like, or by creating amino acid sequence mutants. Covalent derivatives are prepared by linking particular functional groups to amino acid side chains or at the N- or C-termini.

10 The present invention further encompassed fusion proteins comprising the amino acid sequence of IMRRP1 or IMRRP1b or portions thereof linked to an immunoglobulin Fc region. Depending on the portion of the Fc region used, a fusion protein may be expressed as a dimer, through formation of interchain disulfide bonds. If the fusion proteins are made with both heavy and light chains of an antibody, it is possible to form a protein oligomer with as many as four IMRRP1 and/or IMRRP1b regions.

15 The invention also encompasses polynucleotides which encode IMRRP1 and IMRRP1b. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of IMRRP1 or IMRRP1b can be used to generate recombinant molecules which express IMRRP1 and IMRRP1b. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NOS. 1 and 2 as shown in FIGS. 1 and 2.

20 It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding IMRRP1 and IMRRP1b, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon  
25 choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring IMRRP1 and IMRRP1b, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode IMRRP1 or IMRRP1b and their variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring coding sequence for IMRRP1 or IMRRP1b under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding IMRRP1 or IMRRP1b or their derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding IMRRP1 or IMRRP1b and their derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or portions thereof, which encode IMRRP1 or IMRRP1b and their derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding IMRRP1 or IMRRP1b or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NOS: 1 and 2, under various conditions of stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as taught in Wahl, G. M. and S. L. Berger (1987; *Methods Enzymol.* 152:399-407) and Kimmel, A. R. (1987; *Methods of Enzymol.* 152:507-511), and may be used at a defined stringency. In one embodiment, sequences include those capable of hybridizing under moderately stringent conditions (prewashing solution of 2X SSC, 0.5% SOS, 1.0 mM MEDTA, pH 8.0) and hybridization conditions of 50 °C., 5 X SSC, overnight, to the sequences encoding IMRRP1 or IMRRP1b and other sequences which are degenerate to those which encode IMRRP1 or IMRRP1b.



- 17 -

Altered nucleic acid sequences encoding IMRRP1 or IMRRP1b which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent IMRRP1 or IMRRP1b. The encoded protein may also contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent IMRRP1 or IMRRP1b. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of IMRRP1 and IMRRP1b is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the genes encoding IMRRP1 and IMRRP1b. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENCE (US Biochemical Corp. Cleveland, Ohio), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, Ill.), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL

Express Mail Label No. EF 099155765US

(Gaithersburg, Md.). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, Nev.), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, Mass.) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleic acid sequences encoding IMRRP1 or IMRRP1b may be extended  
5 utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) *PCR Methods Applic.* 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent  
15 primers based on a known region (Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186). The primers may be designed using OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Mn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68 °C to about 72 °C. The method uses several restriction enzymes to generate a suitable fragment in the  
20 known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR  
25 amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J. D. et al. (1991; *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries to walk in genomic DNA (Clontech, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon  
5 junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not  
10 yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection  
15 of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is  
20 especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of IMRRP1 or IMRRP1b in appropriate host  
25 cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express IMRRP1 or IMRRP1b.

As will be understood by those of skill in the art, it may be advantageous to produce IMRRP1- or IMRRP1b-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter the IMRRP1 and IMRRP1b encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding IMRRP1 or IMRRP1b may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of IMRRP1 or IMRRP1b activity, it may be useful to encode a chimeric IMRRP1 or IMRRP1b protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the IMRRP1 or IMRRP1b encoding sequence and the heterologous protein sequence, so that IMRRP1 or IMRRP1b may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding IMRRP1 or IMRRP1b may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of IMRRP1 or IMRRP1b, or a portion thereof. For

example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J. Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) *Proteins, Structures and Molecular Principles*, WH Freeman and Co., New York, N.Y.), by reverse-phase high performance liquid chromatography, or other purification methods as are known in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of IMRRP1 or IMRRP1b, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active IMRRP1 or IMRRP1b the nucleotide sequences encoding IMRRP1 or IMRRP1b or functional equivalents, may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding IMRRP1 or IMRRP1b. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell

systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector-enhancers, promoters, 5' and 3' untranslated regions which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or PSORT1 plasmid (Gibco BILL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding IMRRP1 or IMRRP1b, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for IMRRP1 or IMRRP1b. For example, when large quantities are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding IMRRP1 or IMRRP1b may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced, pIN vectors (Van Heeke, G. and S. M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509); and the like. pGEX vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides, as fusion proteins with glutathione S-transferase (GST). In

general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding IMRRP1 or IMRRP1b may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L. E. in McGraw Hill *Yearbook of Science and Technology* (1992) McGraw Hill, New York, N.Y.; pp. 191-196).

An insect system may also be used to express IMRRP1 or IMRRP1b. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. The sequences encoding IMRRP1 or IMRRP1b may be cloned into a non-essential region of the virus such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of IMRRP1 or IMRRP1b will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia* larvae in which IMRRP1 or

IMRRP1b may be expressed (Engelhard, E. K. et al. (1994) *Proc. Nat. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding IMRRP1 or IMRRP1b may be ligated into an adenovirus transcription/ translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing IMRRP1 or IMRRP1b in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous, sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding IMRRP1 or IMRRP1b. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding IMRRP1 or IMRRP1b, their initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only a coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and W138, which



have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express IMRRP1 or IMRRP1b may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) *Cell* 22:817-23) genes which can be employed in *tk<sup>-</sup>* or *aprt<sup>-</sup>* cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate (Wigler, M. et al. (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); *npt*, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin, F. et al (1981) *J. Mol. Biol.* 150:1-14); and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisd*, which allows cells to utilize histinol in place of histidine (Hartman, S. C. and R. C. Mulligan (1988) *Proc. Natl. Acad. Sci.* 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins,  $\beta$  glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific

vector system (Rhodes, C. A. et al. (1995) *Methods Mol. Biol.* 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding IMRRP1 or IMRRP1b is inserted within a marker gene sequence, recombinant cells containing sequences encoding can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding IMRRP1 or IMRRP1b under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding IMRRP1 or IMRRP1b and express IMRRP1 or IMRRP1b may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding IMRRP1 or IMRRP1b can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding IMRRP1 or IMRRP1b. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding IMRRP1 or IMRRP1b to detect transformants containing DNA or RNA encoding IMRRP1 or IMRRP1b. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer.

A variety of protocols for detecting and measuring the expression of IMRRP1 or IMRRP1b, using either polyclonal or monoclonal antibodies specific for the proteins are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay

(RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on IMRRP1 or IMRRP1b is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; *Serological Methods, a Laboratory Manual*, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; *J. Exp. Med.* 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding IMRRP1 or IMRRP1b include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding IMRRP1 or IMRRP1b, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.); and U.S. Biochemical Corp., (Cleveland, Ohio)). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding IMRRP1 or IMRRP1b may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode IMRRP1 or IMRRP1b may be designed to contain signal sequences which direct secretion of IMRRP1 or IMRRP1b through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding IMRRP1 or IMRRP1b to

nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain  
5 utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and IMRRP1 or IMRRP1b may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing IMRRP1 or IMRRP1b and a nucleic acid encoding 6 histidine residues  
10 preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath, J et al. (1992, *Prot. Exp. Purif.* 3:263-281) while the enterokinase cleavage site provides a means for purifying from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D. J. et al. 993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production, fragments of IMRRP1 or IMRRP1b may be produced by direct peptide synthesis using solid-phase techniques (Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of IMRRP1 or IMRRP1b can be  
15 chemically synthesized separately and combined using chemical methods to produce the full length molecule  
20

Chemical and structural homology exists among IMRRP1 or IMRRP1b and the human imidazoline receptor disclosed in *DNA Cell Biol.* 19 (6), 319-329 (2000). Furthermore, IMRRP1 and IMRRP1b are expressed in brain, bone marrow, heart, kidney, liver, lung, lymph  
25 node, placenta, small intestine, spinal cord, spleen testis, and thymus tissues, many of which are associated with the regulation of blood pressure, induction of feeding, stimulation of firing of locus coeruleus neurons, and stimulation of insulin release, as well as the induction of the

expression of glial fibrillary acidic protein independent of the action of alpha-2 adrenoceptors, dysphoric premenstrual syndrome, neurodegenerative disorders such as Alzheimer's disease, opiate addiction, monoamine turnover and therefore nociception, ageing, mood and stroke, salivary disorders and developmental disorders. IMRRP1 and IMRRP1b therefore play an  
5 important role in mammalian physiology.

In another embodiment a vector capable of expressing IMRRP1 or IMRRP1b, or a fragment or derivative thereof, may also be administered to a subject to treat or prevent a physical or psychological disorder, including those listed above.

In another embodiment, agonists or antagonists of IMRRP1 or IMRRP1b may be  
10 administered to a subject to treat or prevent a disorder associated with many neurological conditions and disorders including depression. In one aspect, antibodies which are specific for IMRRP1 or IMRRP1b may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express IMRRP1 or IMRRP1b.

In another embodiment, a vector expressing the complementary or antisense  
15 sequence of the polynucleotide encoding IMRRP1 or IMRRP1b may be administered to a subject to treat or prevent a disorder associated many neurological conditions and disorders including depression.

In another embodiment a vector expressing the complementary or antisense  
20 sequence of the polynucleotide encoding IMRRP1 or IMRRP1b may be administered to a subject to treat or many neurological conditions and disorders including depression associated with expression of IMRRP1 or IMRRP1b.

In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or vectors described above may be administered in combination  
25 with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to

effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Agonists and antagonists or inhibitors of IMRRP1 or IMRRP1b may be produced using methods which are generally known in the art. For example, cloned receptors may be expressed in mammalian cells and compounds can be screened for activity. In addition, purified IMRRP1 or IMRRP1b may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind IMRRP1 or IMRRP1b.

Antibodies specific for IMRRP1 or IMRRP1b may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with or any fragment or oligopeptide of IMRRP1 or IMRRP1b which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Ribi adjuvant R700 (Ribi, Hamilton, Montana), incomplete Freund's adjuvant, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacillus Calmette Guérin) and *Corynebacterium parvum* are especially preferable.

It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to IMRRP1 or IMRRP1b have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. The peptides, fragments or

oligopeptides may comprise a single epitope or antigenic determinant or multiple epitopes. Short stretches of IMRRP1 or IMRRP1b amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to IMRRP1 or IMRRP1b may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42, Cote, R. J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; Cole, S. P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S. L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M. S. et al. (1984) *Nature* 312:604-608; Takeda, S. et al. (1985) *Nature* 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce IMRRP1- or IMRRP1b-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D. R. (1991) *Proc. Natl. Acad. Sci.* 88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) *Proc. Natl. Acad. Sci.* 86:3833-3837; Winter, G. et al. (1991) *Nature* 349:293-299).

Antibody fragments which contain specific binding sites for IMRRP1 or IMRRP1b may also be generated. For example, such fragments include, but are not limited to, the F(ab')<sub>2</sub> fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy

identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. et al. (1989) *Science* 254.1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between IMRRP1 or IMRRP1b and their specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering IMRRP1 or IMRRP1b epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding IMRRP1 or IMRRP1b or any fragment thereof or antisense molecules, may be used for therapeutic purposes. In one aspect, antisense to the polynucleotide encoding IMRRP1 or IMRRP1b may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding IMRRP1 or IMRRP1b. Thus, antisense molecules may be used to modulate IMRRP1 or IMRRP1b activity, or to achieve regulation of gene function. Such technology is well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding IMRRP1 or IMRRP1b.

Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense molecules complementary to the polynucleotides of the genes encoding IMRRP1 or IMRRP1b. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding IMRRP1 or IMRRP1b can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof



which encodes IMRRP1 or IMRRP1b. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the genes encoding IMRRP1 or IMRRP1b, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) In: Huber, B. E. and B. L. Carr, *Molecular and Immunologic Approaches*, Futura Publishing Co., Mt. Kisco, N.Y). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding IMRRP1 or IMRRP1b.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage

site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding IMRRP1 or IMRRP1b. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' *O*-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient as disclosed in U.S. Patent No. 5,399,493 and 5,437,994. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits,

monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of  
5 IMRRP1 or IMRRP1b, antibodies to IMRRP1 or IMRRP1b, mimetics, agonists, antagonists, or inhibitors of IMRRP1 or IMRRP1b. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient  
10 alone, or in combination with other agents, drugs, hormones, or biological response modifiers.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of *Remington's Pharmaceutical Sciences* (Mack Publishing Co.,  
15 Easton, Pa.).  
20

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for  
25 ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing

the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth, and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable

stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

5 The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

10 The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

15 After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of IMRRP1 or IMRRP1b, such labeling would include amount, frequency, and method of administration.

20 Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

25 For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example IMRRP1 or IMRRP1b or fragments thereof antibodies of IMRRP1 or IMRRP1b, agonists, antagonists or inhibitors of IMRRP1 or IMRRP1b which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 microgram, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. In one embodiment, dosages of IMRRP1 or IMRRP1b or fragment thereof from about 1 ng/kg/day to about 10 mg/kg/day, and preferably from about 500 ug/kg/day to about 5 mg/kg/day are expected to induce a biological effect. Those skilled in the art will employ

different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

In another embodiment, antibodies which specifically bind IMRRP1 or IMRRP1b may be used for the diagnosis of conditions or diseases characterized by expression of IMRRP1 or IMRRP1b, or in assays to monitor patients being treated with IMRRP1 or IMRRP1b, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for IMRRP1 or IMRRP1b include methods which utilize the antibody and a label to detect it in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring IMRRP1 or IMRRP1b are known in the art and provide a basis for diagnosing altered or abnormal levels of IMRRP1 or IMRRP1b expression. Normal or standard values for IMRRP1 or IMRRP1b expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to IMRRP1 or IMRRP1b under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of IMRRP1 or IMRRP1b expressed in subject samples, control and disease from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding IMRRP1 or IMRRP1b may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of IMRRP1 or IMRRP1b may be correlated with disease. The diagnostic

assay may be used to distinguish between absence, presence, and excess expression of IMRRP1 or IMRRP1b, and to monitor regulation of IMRRP1 or IMRRP1b levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding IMRRP1 or IMRRP1b or closely related molecules, may be used to identify nucleic acid sequences which encode IMRRP1 or IMRRP1b. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding IMRRP1 or IMRRP1b, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the IMRRP1 or IMRRP1b encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NOS: 1 or 2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring IMRRP1 or IMRRP1b genes.

Means for producing specific hybridization probes for DNAs encoding IMRRP1 or IMRRP1b include the cloning of nucleic acid sequences encoding IMRRP1 or IMRRP1b or derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as <sup>32</sup>P or <sup>35</sup>S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/ biotin coupling systems, and the like.

Polynucleotide sequences encoding IMRRP1 or IMRRP1b may be used for the diagnosis of disorders associated with expression of IMRRP1 and IMRRP1b. Examples of such



disorders or conditions include regulation of blood pressure, hypertension, induction of feeding, stimulation of firing of locus coeruleus neurons, and stimulation of insulin release, as well as the aberrant induction of the expression of glial fibrillary acidic protein independent of the action of alpha-2 adrenoceptors, dysphoric premenstrual syndrome, neurodegenerative disorders such as Alzheimer's disease, opiate addiction, monoamine turnover and therefore nociception, ageing, mood and stroke, salivary disorders and developmental disorders. The polynucleotide sequences encoding IMRRP1 or IMRRP1b may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered IMRRP1 or IMRRP1b expression. Such qualitative or quantitative methods are well known in the art.

The nucleotide sequences encoding IMRRP1 or IMRRP1b may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding IMRRP1 or IMRRP1b in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of IMRRP1 or IMRRP1b, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes IMRRP1 or IMRRP1b, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard

values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding IMRRP1 or IMRRP1b may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'≥3') and another with antisense (3'≥5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of IMRRP1 or IMRRP1b include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P. C. et al. (1993) *J. Immunol. Methods*, 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequences which encode IMRRP1 or IMRRP1b may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a

particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C. M. (1993) *Blood Rev.* 7:127-134, and Trask, B. J. (1991) *Trends Genet.* 7:149-154.

FISH (as described in Verma et al. (1988) *Human Chromosomes: A Manual of Basic Techniques* Pergamon Press, New York, N.Y) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of the gene encoding IMRRP1 or IMRRP1b on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

*In situ* hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R. A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, IMRRP1 or IMRRP1b, their catalytic or

immunogenic fragments or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between IMRRP1 or IMRRP1b and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application W084/03564. In this method, as applied to IMRRP1 or IMRRP1b, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are contacted with IMRRP1 or IMRRP1b or fragments thereof, and washed. Bound IMRRP1 or IMRRP1b are then detected by methods well known in the art. Purified IMRRP1 or IMRRP1b can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding IMRRP1 or IMRRP1b specifically compete with a test compound for binding IMRRP1 or IMRRP1b. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with IMRRP1 or IMRRP1b.

In additional embodiments, the nucleotide sequences which encode IMRRP1 or IMRRP1b may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention. All publications and patents mentioned in the specification are herein incorporated by reference. Various modifications and variations of the

described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

## EXAMPLES

### Example I

#### Method of Isolation of cDNA Encoding IMRRP1 or IMRRP1b

Human imidazoline receptor protein sequence was used as a probe to search the Incyte and public domain EST databases. The search program used was gapped BLAST (Altschul et al., 1997). The top EST hits from the BLAST results were searched back against the non-redundant protein and patent sequence databases. From this analysis, ESTs encoding a potential novel imidazoline receptor was identified based on sequence homology. The Incyte EST (CloneID: 2499870) was selected as a potential novel imidazoline receptor candidate for subsequent analysis.

A PCR primer pair, designed from the DNA sequence of Incyte clone-2499870 was used to amplify a piece of DNA from the clone in which the anti-sense strand of the amplified fragment was biotinylated on the 5' end. This biotinylated piece of double stranded DNA was denatured and incubated with a mixture of single-stranded covalently closed circular cDNA libraries which contain DNA corresponding to the sense strand. The cDNA libraries were total brain tissue libraries obtained from Gibco Life Technologies. Hybrids between the biotinylated DNA and the circular cDNA were captured on streptavidin magnetic beads. Upon thermal release of the cDNA from the biotinylated DNA, the single stranded cDNA was converted into double strands using a primer homologous to a sequence on the cDNA cloning vector. The double stranded cDNA was introduced into *E. coli* by electroporation and the

resulting colonies were screen by PCR, using the original primer pair, to identify the proper cDNA clones. One clone named FL1-18 was sequenced on both strands (Fig 1).

## Example II

### Cellular and Tissue Distribution of IMRRP1

5           The same PCR primer used in the cloning of imidazoline receptor IMRRP1 used to measure the steady state levels of mRNA by quantitative PCR. Briefly, first strand cDNA was made from commercially available mRNA. The relative amount of cDNA used in each assay was determined by performing a parallel experiment using a primer pair for a gene expressed in equal amounts in all tissues, cyclophilin. The cyclophilin primer pair detected small variations in the amount of cDNA in each sample and these data were used for normalization of the data obtained with the primer pair for IMRRP1. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data is presented in Figure 9.

## Example III

### Labeling and Use of Hybridization Probes

15           Hybridization probes derived from SEQ ID NOS: 1 or 2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN, Boston, Mass.). The labeled oligonucleotides are substantially purified with SEPHADEX G-25 superfine resin column (Pharmacia & Upjohn). A portion containing about  $10^7$  counts per minute of each of the sense and antisense oligonucleotides is used in a typical membrane based hybridization  
20 analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II: DuPont NEN).

- 47 -

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, N.H.). Hybridization is carried out for 16 hours at 40 °C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMATAR film (Kodak, Rochester, N.Y.) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, Calif.) for several hours, hybridization patterns are compared visually.

#### Example IV

##### Antisense Molecules

Antisense molecules or nucleic acid sequence complementary to the IMRRP1 or IMRRP1b encoding sequences, or any part thereof, is used to inhibit *in vivo* or *in vitro* expression of naturally occurring IMRRP1 or IMRRP1b. Although use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of IL-17R, as shown in Figures 1 and 2 is used to inhibit expression of naturally occurring IMRRP1 or IMRRP1b. The complementary oligonucleotide is designed from the unique 5' sequence as shown in Figures 1 or 2 and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an IMRRP1 or IMRRP1b encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NOS: 1 or 2 an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or 5' coding sequence of the polypeptide as shown in Figures 1 and 2.

#### Example V

##### Production of IMRRP1 or IMRRP1b Specific Antibodies

IMRRP1 or IMRRP1b that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce

- 48 -

antibodies using standard protocols. The amino acid sequence from SEQ ID NOS: 3 or 4 is analyzed using DNASTAR software (DNASTAR Inc.) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra) and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemacyanin (KLH, Sigma, St. Louis, Mo.) by reaction with *N*-maleimidobenzoyl-*N*-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the rabbit antisera, washing, and reacting with radioiodinated, goat and anti-rabbit IgG.

## Example VI

### Purification of Naturally Occurring IMRRP1 or IMRRP1b Using Specific Antibodies

Naturally occurring or recombinant IMRRP1 or IMRRP1b is substantially purified by immunoaffinity chromatography using antibodies specific for IMRRP1 or IMRRP1b. An immunoaffinity column is constructed by covalently coupling IMRRP1 or IMRRP1b specific antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing IMRRP1 or IMRRP1b is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of IMRRP1 or IMRRP1b (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody—IMRRP1 or IMRRP1b binding (e.g., buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and IMRRP1 or IMRRP1b is collected.



**Example VII****Identification of Molecules which Interact with IMRRP1 or IMRRP1b**

IMRRP1 or IMRRP1b or biologically active fragments thereof are labeled with <sup>125</sup>I Bolton-Hunter reagent (Bolton et al. (1973) *Biochem. J.*, 133:529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled IMRRP1 or IMRRP1b, washed and any wells with labeled IMRRP1 or IMRRP1b complex are assayed. Data obtained using different concentrations of IMRRP1 or IMRRP1b are used to calculate values for the number, affinity, and associate of IMRRP1 or IMRRP1b with the candidate molecules.

**Example VIII****Expression profiling of IMMRP1**

Expression profiling in 12 tissue RNA samples was carried out to show the overall pattern of gene expression in the body. The same PCR primer pair, shown below as Incyte-2499870, that was used to identify IMMRP1 cDNA clones was used to measure the steady state levels of mRNA by quantitative PCR.

INCYTE-2499870-s GCTGGAGACCCTGATTGCA (SEQ ID NO: 5)  
 INCYTE-2499870-ab bTGGACTTGATTGTGGCTTAGGTT (SEQ ID NO: 6)

First strand cDNA was made from commercially available mRNA (Clontech, Stratagene, and LifeTechnologies) and subjected to real time quantitative PCR using a PE 5700 instrument (Applied Biosystems, Foster City, CA) which detects the amount of DNA amplified during each cycle by the fluorescent output of SYBR green, a DNA binding dye specific for double strands. The specificity of the primer pair for its target is verified by performing a thermal denaturation profile at the end of the run which gives an indication of the number of different DNA sequences present by determining melting T<sub>m</sub>. In the case of the FGFR1ΔCP primer pair, only one DNA fragment was detected having a homogeneous melting point. Contributions of contaminating genomic DNA to the assessment of tissue abundance is controlled for by performing the PCR with first strand made with and without reverse

transcriptase. In all cases, the contribution of material amplified in the no reverse transcriptase controls was negligible.

Small variations in the amount of cDNA used in each tube was determined by performing a parallel experiment using a primer pair for cyclophilin, a gene expressed in equal amounts in all tissues. These data were used to normalize the data obtained with the IMMRP1 primer pair. The PCR data was converted into a relative assessment of the difference in transcript abundance amongst the tissues tested and the data are presented in bar graph form in Figure 10. Transcripts corresponding to IMMRP1 were found in all the additional RNAs tested with the highest amount present in the testis (like that of the first panel tested). Relatively high expression was also observed in the salivary gland and the fetal brain.

The quantitative PCT was performed by determining the number of reactions and amount of mix needed. All samples were run in triplicate, so each sample tube need 3.5 reactions worth of mix. This is determined by the following formula:  $2 \times \# \text{ tissue samples} + 1 \text{ no template control} + 1 \text{ for pipetting error}$ .

The reaction mixture was prepared as follows.

Components	vol/rxn
2X SybrGreen Master Mix	25 microliters
water	23.5 microliters
primer mix (10 $\mu$ M ea.)	0.5 microliters
cDNA (2.5 ng/ $\mu$ L)	1 microliter

An aliquot 171.5  $\mu$ L of mix was added to each to sample tubes followed by the addition of 1  $\mu$ L of cDNA. Each sample tube was mixed gently and spun down. An aliquot of 3 x 50  $\mu$ L was added to an optical plate and analyzed.

## REFERENCES

- 5 Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. L. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acid Res.* 25, 3389-3402.
- 10 Escriba, P. V., Ozaita, A., Miralles, A., Reis, D. J., and Garcia-Sevilla, J. A. (1995). Molecular characterization and isolation of a 45-kilodalton imidazoline receptor protein from the rat brain. *Molec. Brain. Res.* 32, 187-196.
- Farsang, C., and Kapocsi, J. (1999). Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). *Brain Res. Bull.* 49, 317-331.
- Garcia-Sevilla, J. A., Escriba, P. V., and Guimon, J. (1999). Imidazoline receptors and human brain disorders. *Ann. N. Y. Acad. Sci.* 21, 392-409.